ECDC is monitoring reports from three countries (France, the United Kingdom and the United States) of cases of invasive meningococcal disease (IMD) associated with travel to the Kingdom of Saudi Arabia (KSA).
Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
European Immunization Week (EIW) is marked across Europe every year in the final week of April. It aims to raise awareness of the importance of immunisation for the general health and well-being of the European and wider population.
In connection with the European Immunization Week, ECDC releases data indicating an increase in cases of vaccine-preventable diseases such as measles and pertussis, after decreased levels during the COVID-19 pandemic.
In this episode we take a closer look at the data collection for respiratory viruses and why we should take this more seriously than just a cough or a sneeze.
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.
ECDC and World Health Organization (WHO) Regional Office for Europe have jointly developed the European Respiratory Virus Surveillance Summary (ERVISS), an interactive surveillance data dashboard for influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that also features a weekly epidemiological summary.
As autumn moves to winter, the WHO/Europe, EC and ECDC are issuing a clear, urgent message: people who remain unprotected against both COVID-19 and seasonal influenza – especially the most vulnerable and at-risk – should take up any offer for vaccination to prevent or mitigate the impact of these co-circulating respiratory infections.